Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline
CompanyDeals

Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline

CompanyLegal / IP

Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court

CompanyDrug

Sichuan Biokin’s Iza-Bren Becomes World’s First EGFR×HER3 Bispecific ADC with NDA Accepted by China’s NMPA

CompanyDeals

SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health

CompanyDeals

Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy

Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency
CompanyDrug

Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency

CompanyDeals

Medtronic Completes $550 Million Acquisition of Scientia Vascular to Strengthen Neurovascular Portfolio

Sanofi's Tzield Receives FDA Approval to Preserve Insulin Production in Recently Diagnosed Type 1 Diabetes
CompanyDrug

Sanofi’s Tzield Receives FDA Approval to Preserve Insulin Production in Recently Diagnosed Type 1 Diabetes

Roche's VENTANA PTEN Assay Receives FDA Approval as First Companion Diagnostic for AstraZeneca's Truqap in Prostate Cancer
CompanyMedical Device

Roche’s VENTANA PTEN Assay Receives FDA Approval as First Companion Diagnostic for AstraZeneca’s Truqap in Prostate Cancer

Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer
CompanyDrug

Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer

AstraZeneca's Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer
CompanyDrug

AstraZeneca’s Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer

Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO
CompanyDeals

Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO